Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

itation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data for pirfenidone reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in a presentation of the CAPACITY data that the company expects to make at the American Thoracic Society (ATS) in the second quarter of 2009, and/or in a scientific publication.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  HireLifeScience.com, the premier career networking website for ... th annual career fair at The NJ ... Edison, NJ on September ... Actavis and AstraZeneca.  Additional Pharmaceutical, Biotechnology and Medical ... & Johnson, MedImmune, DSM Nutritional Products, LifeCell, Duke ...
(Date:6/3/2015)... 2015 The National Center for ... record by scaling CD-adapco’s flagship simulation tool STAR-CCM+® ... , STAR-CCM+ is a comprehensive multidisciplinary engineering ... innovation and lower product development costs. CD-adapco joined ... manufacturer Cray to push the code to new ...
(Date:6/3/2015)... 03, 2015 From smart street lighting ... part in enabling success in dealing with important Societal ... leaders helped bring focus to the role and further ... Photonics21 annual meeting last week in Brussels. ... held 28 and 29 May at the Hotel Le ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced the ... , Test, Application & End User - Forecast to ... bioburden testing market is expected to reach $565.6 Million ... a CAGR of 9.8% from 2014 to 2019 ... market is segmented into consumables and instruments. The consumables ...
Breaking Biology Technology:AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... a private,biotechnology company and leading developer of clean ... Singapore,Pte. Ltd. (CLS). CLS is the company,s first ... the company,s research and development operations in the,U.S. ... business in,both the innovator and generics markets. ...
... Inc. (Amex: PLX ), announced today the pricing ... common stock at a,public offering price of $5.00 per ... underwriters to purchase up to 1,500,000 additional shares of,common ... Bank is acting as sole book-running manager for this,offering. ...
... Inc. (Nasdaq: HGSI ) today announced that it ... for the quarter ended,September 30, 2007. These results are ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) The conference call will ... Thursday, November 1, 2007, at 11:00 am Eastern Time. ...
Cached Biology Technology:Codexis Opens Singapore Laboratory 2Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... at the IRCM in Montral found a possible alternative ... the IRCM,s President and Scientific Director, the team discovered ... could be targeted to develop a new approach that ... as chemotherapy and radiation therapy. The study,s results are ...
... created a new method to generate bone cells which could ... fractures or those who need hip replacement surgery due to ... Emmajayne Kingham at the University of Southampton in collaboration with ... Small , cultured human embryonic stem cells on to the ...
... for Valentine,s Day, the American Chemical Society (ACS), the world,s ... video today featuring five chemistry facts that highlight why chocolate, ... by the ACS Office of Public Affairs, is available at ... of chocolate contains hundreds of compounds, many with beneficial properties. ...
Cached Biology News:Researchers discover 'Achilles' heel' for lymphoid leukemia 2Stem cell breakthrough could lead to new bone repair therapies on nanoscale surfaces 2